AHN 649

Drug Profile

AHN 649

Latest Information Update: 27 Nov 2007

Price : $50

At a glance

  • Originator Walter Reed Army Institute of Research
  • Class Antidementias; Antiepileptic drugs; Neuroprotectants
  • Mechanism of Action Glutamate receptor antagonists; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Stroke

Most Recent Events

  • 27 Oct 2007 Discontinued - Preclinical for Stroke in USA (unspecified route)
  • 26 Nov 1999 A study has been added to the adverse events and Neurological Disorders pharmacodynamics section
  • 02 Feb 1998 A study has been added to the Neurological disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top